Oncology Medical News about Genistein

Your Unread Messages

See All

Hello, Mary O'connor
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Genistein reverses hypermethylation and induces active histone modifications in tumor suppressor gene B-Cell translocation gene 3 in prostate cancer
Cancer, 11/06/09

Majid S et al. – This is the first report to show that BTG3 is silenced in prostate cancer and can be reactivated by genistein–induced promoter demethylation and active histone modification. Genistein showed similar effects to that of 5Aza–C, which is currently undergoing phase 2 clinical trials as a treatment for prostate cancer. Because genistein is a natural, nontoxic, and dietary isoflavone, these results indicate that genistein is a novel, advantageous therapeutic agent for treating prostate cancer.

<< Previous
Mitoxantrone and etoposide in patients with newly diagnosed acute...

Next >>
BCL2 -938C>A polymorphism and disease progression in chronic...

Marked Individual Variation in Isoflavone Metabolism After a Soy Challenge Can Modulate the Skeletal Effect of Isoflavones in Premenopausal Women
Journal of Korean Medical Science, 10/06/09 Relevance Score: 84%

Targeting CWR22Rv1 Prostate Cancer Cell Proliferation and Gene Expression by Combinations of the Phytochemicals EGCG, Genistein and Quercetin
Anticancer Research, 11/10/09 Relevance Score: 83%

Inhibitory effects of genistein on metastasis of human hepatocellular carcinoma
World Journal of Gastroenterology, 10/27/09 Relevance Score: 83%

Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification
Investigational New Drugs, 10/08/09 Relevance Score: 80%